Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States, Canada, and Hong Kong. It offers an array of next-generation human heart tissue prototypes. The company provides a range of bioengineering technologies known as the MyHeart platform, including the human mini-heart 'novoHeart' that is capable of pumping and ejecting fluid. Its MyHeart platform develops cell-based cardiac regenerative therapies. The company's MyHeart products include human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. It also provides screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. The company is based in Vancouver, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone604-398 3170
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$337,843.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Novoheart (CVE:NVH) Frequently Asked Questions
What is Novoheart's stock symbol?
Novoheart trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NVH."
Has Novoheart been receiving favorable news coverage?
Media stories about NVH stock have been trending very positive on Friday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novoheart earned a news impact score of 3.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Novoheart.
Who are some of Novoheart's key competitors?
Some companies that are related to Novoheart include Bellus Health (BLU), Starpharma (SPL), Biotest (BIO), Pfenex (PFNX), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Neptune Wellness Solutions (NEPT), Rafael (RFL), ProMetic Life Sciences (PLI), Neuren Pharmaceuticals (NEU), Theratechnologies (TH), Silence Therapeutics (SLN), IMV (IMV), Resverlogix (RVX) and Emblem (EMC).
What other stocks do shareholders of Novoheart own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Novoheart investors own include InVitae (NVTA) and Natera (NTRA).
Who are Novoheart's key executives?
Novoheart's management team includes the folowing people:
- Dr. Ronald Li B.Sc. (Hons), Ph.D., Scientific Co-Founder, CEO & Director (Age 48)
- Prof. Kevin Costa B.S., Ph.D., Chief Scientific Officer & Scientific Co-Founder (Age 53)
- Dr. Camie Chan B.S., B.Sc. (Hons), M.Sc., Ph.D., Interim CFO, COO, Corp. Sec. & Director (Age 45)
- Prof. Michelle Khine, Scientific Co-Founder & Member of Scientific Advisory Board
- Dr. Bill A. Williams, Sr. VP of Commercial Operations
How do I buy shares of Novoheart?
Shares of NVH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Novoheart's stock price today?
One share of NVH stock can currently be purchased for approximately C$0.62.
How big of a company is Novoheart?
What is Novoheart's official website?
How can I contact Novoheart?
The company can be reached via phone at 604-398 3170.
MarketBeat Community Rating for Novoheart (CVE NVH)
MarketBeat's community ratings are surveys of what our community members think about Novoheart and other stocks. Vote "Outperform" if you believe NVH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVH will underperform the S&P 500 over the long term. You may vote once every thirty days.
